Research programme: diabetes vaccine - AFFiRiS

Drug Profile

Research programme: diabetes vaccine - AFFiRiS

Latest Information Update: 08 Sep 2016

Price : $50

At a glance

  • Originator AFFiRiS
  • Class Peptide vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Type 2 diabetes mellitus
  • Discontinued Diabetes mellitus

Most Recent Events

  • 08 Sep 2016 Discontinued - Preclinical for Diabetes mellitus in Austria (Parenteral) (AFFiRis pipeline, September 2016)
  • 08 Sep 2016 Early research in Type-2 diabetes mellitus in Austria (Parenteral) before September 2016 (AFFiRis pipeline, September 2016)
  • 25 Jun 2014 Research programme: diabetes vaccine - AFFiRiS is available for licensing as of 25 Jun 2014. http://www.affiris.com/index_en.html
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top